Results 161 to 170 of about 29,557,581 (269)

A bayesian model averaging approach with non-informative priors for cost-effectiveness analyses in health economics [PDF]

We consider the problem of assessing new and existing technologies for their cost-effectiveness in the case where data on both costs and effects are available from a clinical trial, and we address it by means of the cost-effectiveness acceptability curve.
Caterina Conigliani
core  

Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son, Inyoung Hwang, Sang Won Lee, Yun Kim   +3 more
wiley   +1 more source

Cost benefit analysis vs. referenda [PDF]

We consider a planner who chooses between two possible public policies and ask whether a referendum or a cost benefit analysis leads to higher welfare.
Matthew A. Turner, Martin J. Osborne
core  

Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Blood biomarkers are increasingly critical for non‐invasive Alzheimer's Disease (AD) diagnostics and research but typically require on‐site processing. Remote point‐of‐care collection methods could enhance biomarker testing in clinical and research settings.
Sara Ho, Ziling Shen, Alexandria Lewis, Megha Patel, Anny Zheng, Gianna Proscino, Thaovy Ho, Jiangxia Wang, Marilyn Albert, Abhay Moghekar   +9 more
wiley   +1 more source

Cost–consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context

, 2014
Piercarla Schinco,1 Dorina Cultrera,2 Federica Valeri,1 Alessandra Borchiellini,1 Michela Mantuano,3 Francesca Gorla,3 Alessia Savarese,3 Cristina Teruzzi3 1Hemostasis and Thrombosis Unit, Molinette Hospital of Turin, 2Department of Hematology ...
Valeri F, Teruzzi C, Gorla F, Savarese A, Cultrera D, Mantuano M, Schinco P, Borchiellini A   +7 more
core  

Association Between Neurofilament Light Chain and Real‐World Ambulatory Function in Progressive MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurofilament light chain (NfL) is a biomarker of neuroaxonal injury in multiple sclerosis (MS), yet associations with functional outcomes remain unclear. Longitudinal associations between serum NfL (sNfL) and daily step count (STEPS) from wearable devices were assessed in a large international progressive MS cohort.
Gabby B. Joseph, Megan McCune, Riley Bove, Ahmed Abdelhak, Bruce A. C. Cree, Valerie J. Block   +5 more
wiley   +1 more source

Pre-emptive <i>CYP2C19</i> genotyping and voriconazole exposure in pediatric hematology patients at risk of aspergillosis: an exploratory randomized pilot study with a cost-consequence analysis. [PDF]

Front Pharmacol
Monserrat-Villatoro J, Bueno D, Estébanez M, Mozo Y, Rosas-Alonso R, Antón C, Otero MJ, Guerra-García P, Díaz-Villamarín X, Arias P, Pérez-Martínez A, Abad-Santos F, Carcas AJ, García-García I, Borobia AM.   +14 more
europepmc   +1 more source

Subjective Cognitive Concerns and Cognitive Trajectories in Parkinson's Disease: Biomarker Impact

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the relationship of subjective cognitive concerns (SCC) with biomarkers of Alzheimer's disease (AD), neurodegeneration, and Parkinson's disease (PD) and domain‐specific cognitive trajectories among cognitively unimpaired persons with de novo PD. Method Cognitively unimpaired participants with SCC (n = 294) and without SCC (
Francesca V. Lopez, Fareshte Erani, Katherine J. Bangen, David G. Coughlin, Douglas Galasko, Kelsey R. Thomas   +5 more
wiley   +1 more source

A Cost Consequence Analysis of Seven Diagnostic Strategies for Ovarian Cancer: A Model-Based Economic Evaluation. [PDF]

BJOG
Perry SJ, Griffin D, Williams EV, Roberts TE, Kwong FL, Williams S, Deeks J, Scandrett K, Agarwal R, Sundar SS, Monahan M.   +10 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source